Clinical Trial Update: Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

View source ↗

Summary

Marketing approval of nilotinib for adult chronic myeloid leukemia in imatinib-resistant or intolerant patients across blast crisis, accelerated phase, or chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Status: APPROVED_FOR_MARKETING